+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Immunoglobulin Product Market by Source, Product Type, Route of Administration, Distribution Channel, Application - Global Forecast to 2030- Product Image
Immunoglobulin Product Market by Source, Product Type, Route of Administration, Distribution Channel, Application - Global Forecast to 2030- Product Image
Sale

Immunoglobulin Product Market by Source, Product Type, Route of Administration, Distribution Channel, Application - Global Forecast to 2030

  • PDF Icon

    Report

  • 195 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4904902
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Immunoglobulin Product Market is undergoing significant transformation, propelled by technology advances, evolving clinical practices, and policy shifts. For decision-makers evaluating investment and growth options in the biotherapeutics sector, understanding these market dynamics is critical to optimizing strategic direction.

Market Snapshot: Immunoglobulin Product Market

The Immunoglobulin Product Market grew from USD 18.92 billion in 2024 to USD 21.39 billion in 2025. It is expected to continue growing at a CAGR of 12.66%, reaching USD 38.72 billion by 2030. Market growth is driven by the transition from plasma-derived to recombinant therapies, increased prevalence of chronic disorders, and greater integration of digital health technologies. The market’s ability to address complex immune and neurological conditions contributes to its broadening clinical impact and relevance across global healthcare systems.

Scope & Segmentation

  • Source: Includes Pooled Human Plasma and Recombinant origins, each supporting distinct clinical and operational requirements.
  • Product Type: Covers Hyperimmune Globulin (targeted prophylaxis and outbreak response) and Standard Immunoglobulin (maintenance for immune deficiencies).
  • Route of Administration: Addresses Intravenous (hospital-based intervention), Subcutaneous (home-based self-administration), and Intramuscular (specific, emergent uses) formats.
  • Distribution Channel: Considers Hospital Pharmacies (inpatient delivery), Retail Pharmacies (outpatient and chronic care), and Online Pharmacies (digital, home-access solutions).
  • Application: Encompasses Hematological Disorders (e.g., hemolytic anemia, immune thrombocytopenia), Infectious Diseases (e.g., hepatitis A, rubella, varicella), Neurological Disorders (including CIDP, Guillain-Barré syndrome, myasthenia gravis), and Primary Immune Deficiency syndromes.
  • Regions: Analyzes Americas (U.S., Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (e.g., UK, Germany, South Africa, Turkey, Israel, Norway), and Asia-Pacific (China, India, Japan, Australia, Singapore, and others).
  • Leading Companies: Features CSL Behring, Grifols S.A., Takeda Pharmaceutical Company, Octapharma AG, Kedrion S.p.A., Biotest AG, LFB S.A., Bio Products Laboratory Limited, GC Pharma Co., and Shanghai RAAS Blood Products Co.

Key Takeaways for Decision-Makers

  • Recombinant immunoglobulin technology is driving shifts in manufacturing, offering enhanced purity and efficiency and enabling diversification beyond traditional plasma-derived approaches.
  • Decentralized administration—particularly subcutaneous and home-based methods—is expanding, in response to patient preference and evolving care models, supporting adherence and easing healthcare infrastructure burden.
  • Digital health integration, including telemedicine and online pharmacy distribution, is streamlining patient access while requiring new regulatory and operational frameworks for safety and compliance.
  • Industry leaders are prioritizing lean manufacturing, quality control digitalization, and vigilant pharmacovigilance to maintain supply chain resilience and high safety standards.
  • Collaborative partnerships and regional expansion strategies are increasingly crucial for addressing capacity gaps, expanding market presence, and improving patient access across both mature and developing regions.

Tariff Impact: U.S. Market Dynamics

New U.S. tariffs introduced in 2025 are intensifying pricing pressures and forcing immunoglobulin producers to adjust procurement and sourcing strategies. With higher operational costs affecting manufacturers dependent on imported raw materials, there is a notable shift to domestic plasma collection and local production. This shift requires significant investment in capacity-building and compliance, which in turn may spur innovation in supply chain management and foster vertical integration among stakeholders. Healthcare providers are recalibrating formulary selections and utilization patterns to balance cost efficiency with care standards in the face of these policy changes.

Methodology & Data Sources

This report utilizes a rigorous blend of primary and secondary research. Primary sources include interviews with industry leaders, regulatory experts, and clinical specialists to gain direct market insight. Comprehensive secondary research supports findings via peer-reviewed publications, regulatory filings, white papers, and proprietary databases. Data is validated through triangulation with external subject matter experts and iterative analytical review, ensuring reliability and actionable intelligence for market assessment.

Why This Report Matters

  • Enables senior leaders to plan investments and resource allocation by presenting a structured analysis of immunoglobulin market trends and operational challenges.
  • Facilitates benchmarking of strategic initiatives for addressing technology adoption, regional expansion, and regulatory barriers within this dynamic biotherapeutics segment.
  • Enhances competitive positioning by mapping innovation trends and supply chain optimizations with direct impact on market access and patient care.

Conclusion

Industry stakeholders in the immunoglobulin market face a complex, evolving landscape shaped by technology, regulation, and patient expectations. Proactive adaptation and cross-sector collaboration are essential for sustainable growth and for ensuring continued patient access to advanced immunoglobulin therapies.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Immunoglobulin Product Market, by Source
8.1. Introduction
8.2. Pooled Human Plasma
8.3. Recombinant
9. Immunoglobulin Product Market, by Product Type
9.1. Introduction
9.2. Hyperimmune Globulin
9.3. Standard Immunoglobulin
10. Immunoglobulin Product Market, by Route of Administration
10.1. Introduction
10.2. Intramuscular
10.3. Intravenous
10.4. Subcutaneous
11. Immunoglobulin Product Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Immunoglobulin Product Market, by Application
12.1. Introduction
12.2. Hematological Disorders
12.2.1. Hemolytic Anemia
12.2.2. Idiopathic Thrombocytopenic Purpura
12.3. Infectious Diseases
12.3.1. Hepatitis a
12.3.2. Rubella
12.3.3. Varicella
12.4. Neurological Disorders
12.4.1. Chronic Inflammatory Demyelinating Polyneuropathy
12.4.2. Guillain-Barre Syndrome
12.4.3. Myasthenia Gravis
12.5. Primary Immune Deficiency
12.5.1. Common Variable Immunodeficiency
12.5.2. Severe Combined Immunodeficiency
12.5.3. X-Linked Agammaglobulinemia
13. Americas Immunoglobulin Product Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Immunoglobulin Product Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Immunoglobulin Product Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. CSL Behring
16.3.2. Grifols, S.A.
16.3.3. Takeda Pharmaceutical Company Limited
16.3.4. Octapharma AG
16.3.5. Kedrion S.p.A.
16.3.6. Biotest AG
16.3.7. LFB S.A.
16.3.8. Bio Products Laboratory Limited
16.3.9. GC Pharma Co., Ltd.
16.3.10. Shanghai RAAS Blood Products Co., Ltd.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. IMMUNOGLOBULIN PRODUCT MARKET MULTI-CURRENCY
FIGURE 2. IMMUNOGLOBULIN PRODUCT MARKET MULTI-LANGUAGE
FIGURE 3. IMMUNOGLOBULIN PRODUCT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. IMMUNOGLOBULIN PRODUCT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. IMMUNOGLOBULIN PRODUCT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. IMMUNOGLOBULIN PRODUCT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY POOLED HUMAN PLASMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HYPERIMMUNE GLOBULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY STANDARD IMMUNOGLOBULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMOLYTIC ANEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEPATITIS A, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY RUBELLA, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY VARICELLA, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY GUILLAIN-BARRE SYNDROME, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY MYASTHENIA GRAVIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COMMON VARIABLE IMMUNODEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SEVERE COMBINED IMMUNODEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY X-LINKED AGAMMAGLOBULINEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 60. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 61. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 62. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 65. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 66. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 67. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 68. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 69. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 70. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 71. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 74. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 75. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 76. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 77. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 106. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 108. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 114. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 115. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 116. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 117. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 119. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 120. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 121. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 122. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 123. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 124. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 125. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 126. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 129. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 130. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 131. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 132. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 133. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 134. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 135. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 136. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 138. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 139. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 140. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 141. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 142. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 143. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 144. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 147. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 148. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 149. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 150. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 151. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 152. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 153. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 155. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 156. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 157. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 158. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 159. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 160. UNITED ARAB EMIRATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 161. UNITED ARAB EMIRATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 162. UNITED ARAB EMIRATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. UNITED ARAB EMIRATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 164. UNITED ARAB EMIRATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 165. UNITED ARAB EMIRATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 167. UNITED ARAB EMIRATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 168. UNITED ARAB EMIRATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 169. SAUDI ARABIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 170. SAUDI ARABIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 171. SAUDI ARABIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. SAUDI ARABIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 173. SAUDI ARABIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 174. SAUDI ARABIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 176. SAUDI ARABIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 177. SAUDI ARABIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 178. SOUTH AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 179. SOUTH AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 180. SOUTH AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 181. SOUTH AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. SOUTH AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 183. SOUTH AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 184. SOUTH AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 185. SOUTH AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 186. SOUTH AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 187. DENMARK IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 188. DENMARK IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 189. DENMARK IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. DENMARK IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. DENMARK IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 192. DENMARK IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 193. DENMARK IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 194. DENMARK IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 195. DENMARK IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 196. NETHERLANDS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 197. NETHERLANDS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 205. QATAR IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 206. QATAR IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 207. QATAR IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 208. QATAR IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 209. QATAR IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 210. QATAR IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 211. QATAR IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 212. QATAR IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 213. QATAR IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 214. FINLAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 215. FINLAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 216. FINLAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 217. FINLAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. FINLAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 219. FINLAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 220. FINLAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 221. FINLAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 222. FINLAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 223. SWEDEN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 224. SWEDEN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 225. SWEDEN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 226. SWEDEN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 227. SWEDEN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 228. SWEDEN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 229. SWEDEN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 230. SWEDEN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 231. SWEDEN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 232. NIGERIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 233. NIGERIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 234. NIGERIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 235. NIGERIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 240. NIGERIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 241. EGYPT IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 242. EGYPT IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 243. EGYPT IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. EGYPT IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 245. EGYPT IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 246. EGYPT IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 247. EGYPT IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 248. EGYPT IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 249. EGYPT IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 250. TURKEY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 251. TURKEY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 252. TURKEY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 253. TURKEY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 254. TURKEY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 255. TURKEY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 256. TURKEY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 257. TURKEY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 258. TURKEY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 259. ISRAEL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 260. ISRAEL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 261. ISRAEL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 262. ISRAEL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 263. ISRAEL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 264. ISRAEL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 266. ISRAEL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 267. ISRAEL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 268. NORWAY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 269. NORWAY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 270. NORWAY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 271. NORWAY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 272. NORWAY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 273. NORWAY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 274. NORWAY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 275. NORWAY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 276. NORWAY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 277. POLAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 278. POLAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 279. POLAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 280. POLAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 281. POLAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 282. POLAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 283. POLAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 284. POLAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 285. POLAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 286. SWITZERLAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 287. SWITZERLAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 288. SWITZERLAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 289. SWITZERLAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 290. SWITZERLAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 291. SWITZERLAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 292. SWITZERLAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 293. SWITZERLAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 294. SWITZERLAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 295. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 296. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 297. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 298. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 299. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 300. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 301. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 302. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 303. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 304. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 305. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 306. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 307. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 308. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 309. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 310. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 311. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 312. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 313. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 314. INDIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 315. INDIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 316. INDIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 317. INDIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY DI

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Immunoglobulin Product market report include:
  • CSL Behring
  • Grifols, S.A.
  • Takeda Pharmaceutical Company Limited
  • Octapharma AG
  • Kedrion S.p.A.
  • Biotest AG
  • LFB S.A.
  • Bio Products Laboratory Limited
  • GC Pharma Co., Ltd.
  • Shanghai RAAS Blood Products Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages195
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 21.39 Billion
Forecasted Market Value ( USD ) by 2030 $ 38.72 Billion
Compound Annual Growth Rate12.6%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Intravenous Immunoglobulin Market by End User, Product Type, Patient Type, Distribution Channel, Indication - Global Forecast to 2030 - Product Image

Intravenous Immunoglobulin Market by End User, Product Type, Patient Type, Distribution Channel, Indication - Global Forecast to 2030

  • Report
  • 187 Pages
  • Global
From
Subcutaneous Immunoglobulin Market by Indication, End User, Delivery Mode, Formulation, Strength - Global Forecast to 2030 - Product Image

Subcutaneous Immunoglobulin Market by Indication, End User, Delivery Mode, Formulation, Strength - Global Forecast to 2030

  • Report
  • 188 Pages
  • Global
From
Intravenous Immunoglobulin Market Size, Share & Trends Analysis Report By Application (Immunodeficiency Diseases), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Intravenous Immunoglobulin Market Size, Share & Trends Analysis Report By Application (Immunodeficiency Diseases), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 153 Pages
  • Global
From
Intravenous Immunoglobulin Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025-2033 - Product Image

Intravenous Immunoglobulin Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025-2033

  • Report
  • 175 Pages
  • Global
From
Subcutaneous Immunoglobulin - Global Strategic Business Report - Product Image

Subcutaneous Immunoglobulin - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From

About the Immunoglobulin Market

The Immunoglobulin market is a segment of the Immune Disorders Drugs market, which focuses on treatments for conditions related to the immune system. Immunoglobulin (Ig) is a type of protein found in the blood that helps fight infection and disease. It is used to treat a variety of immune-related conditions, including autoimmune diseases, allergies, and infections. Immunoglobulin therapies are typically administered intravenously or subcutaneously, and can be used to replace or supplement the body's natural Ig production. The Immunoglobulin market is highly competitive, with a number of companies offering a range of products. These products vary in terms of dosage, delivery method, and cost. Companies in the market are focused on developing new therapies and improving existing ones, as well as expanding their product portfolios. Some of the major companies in the Immunoglobulin market include CSL Behring, Grifols, Kedrion, Octapharma, and Shire. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.